Medical Sciences

Medical Sciences

A randomized, double-blind, placebo and active controlled, multicenter, phase 3 study to access the efficacy and safety of Filgotinib administered for 52 weeks in combination with Methotrexate (MTX) to subjects with moderately to severely active rheumatoid arthritis, who have an inadequate response to methotrexate

A randomized, Double-blind, Placebo and Active controlled, Multicenter, Phase 3 Study to Access the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis who Are Naive to MTX Therapy

Pages

Subscribe to RSS - Medical Sciences